Patient Perspective on Climate Impact of Inhalers
Asthma
About this trial
This is an interventional other trial for Asthma focused on measuring Asthma, Inhalers, Environment, Climate impact
Eligibility Criteria
Inclusion Criteria: 18 years of age or older Followed in the asthma clinic at the Montreal Chest Institute or the Montreal General Hospital. Confirmed diagnosis of asthma presenting for a follow up visit for their asthma (defined as positive methacholine challenge test or confirmed reversibility of lung function 12% increase FEV1 (forced expiratory volume) or 200ml absolute value increase post bronchodilator). On an inhaled steroid for the treatment of asthma for maintenance as well as Ventolin MDI as a rescue inhaler. Stable asthma -not currently being evaluated for an acute asthma exacerbation and no Emergency Room visits for asthma within the last 30 days. Adequate lung function with a FEV1 of at least 50% and, where available, a peak inspiratory flow (PIF) of under 60L/m for use of a DPI and MDI.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Asthma patients
Low risk educational intervention. The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler. Also 5 selected asthma providers will be asked to fill a questionnaire on their perspectives on the climate impact of inhalers and their approach to inhaler rotation. This may also be supplemented with a phone interview